Oncology – Skin | Links Medicus Content Curation & Alerts in Medicine

Consensus Paper | Revision of classification system for reporting on skin biopsies of melanocytic lesions

15 Jan, 2023 | 20:17h | UTC

Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement – JAMA Network Open

Commentaries:

Classification system for reporting on skin biopsies of melanocytic lesions – University of California – Los Angeles Health Sciences

MPATH-Dx Version 2.0 Simplifies Classification of Melanoma – HealthDay

Commentary on Twitter

American and international #dermatopathologists revise Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis schema. MPATH-Dx V2.0 improves standardized diagnostic reporting and patient management of #melanoma. https://t.co/G0fluzq5fs

— JAMA Network Open (@JAMANetworkOpen) January 12, 2023

RCT | Tumor-infiltrating lymphocyte therapy vs. Ipilimumab in advanced melanoma.

8 Dec, 2022 | 12:51h | UTC

Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Patient’s own immune cells effective as living medicine for melanoma – Netherlands Cancer Institute

Skin cancer in solid organ transplant recipients: a review for the non-dermatologist.

27 Nov, 2022 | 22:02h | UTC

Skin Cancer in Solid Organ Transplant Recipients: A Review for the Nondermatologist – Mayo Clinic Proceedings

Single-arm P2 study | Neoadjuvant relatlimab and nivolumab in resectable melanoma.

8 Nov, 2022 | 12:11h | UTC

Neoadjuvant relatlimab and nivolumab in resectable melanoma – Nature

News Release: Neoadjuvant immunotherapy with relatlimab and nivolumab is safe and effective in stage III melanoma – MD Anderson News Release

Commentary on Twitter

In a phase II trial of neoadjuvant & adjuvant nivolumab+relatlimab in 30 pts with stage III or oligometastatic stage IV melanoma, the pCR rate was 57%, with a 70% pRR; 1- & 2-yr RFS was 100% & 92% vs 88% & 55% for pts with vs without any path. response: https://t.co/2ypNeUTpwb

— NatureRevClinOncol (@NatRevClinOncol) November 1, 2022

RCT | Dabrafenib and Trametinib vs. Nivolumab and Ipilimumab for patients with advanced BRAF-mutant melanoma.

1 Nov, 2022 | 12:06h | UTC

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134 – Journal of Clinical Oncology

News Release: Advanced melanoma survival improves significantly when immunotherapy is given before targeted therapy – Georgetown University Medical Center

Commentary: Treatment Sequence Studied for Advanced BRAF-Mutant Melanoma – HealthDay

RCT | Adjuvant Nivolumab plus Ipilimumab vs. Nivolumab alone in patients with resected Stage IIIB-D or Stage IV melanoma.

30 Sep, 2022 | 12:33h | UTC

Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) – Journal of Clinical Oncology

Phase 2 RCT | Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma.

19 Sep, 2022 | 12:32h | UTC

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial – The Lancet (free registration required for full-text)

Commentary: Dual checkpoint inhibitor blockade shows promise as first-line and salvage therapy for Merkel cell carcinoma patients – H. Lee Moffitt Cancer Center & Research Institute

Phase 2 RCT | Sequencing of Ipilimumab plus Nivolumab and Encorafenib plus Binimetinib for untreated BRAF-mutated metastatic melanoma.

14 Sep, 2022 | 13:01h | UTC

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Sequential Treatment With Immunotherapy and Targeted Therapy Denotes OS Benefit in BRAF-Mutant Melanoma – OncLive

Commentary on Twitter

Data from the phase II SECOMBIT trial of treatment sequencing for BRAF-mutant metastatic melanoma suggests that nivo+ipi followed by encorafenib + binimetinib results in better OS than the reverse sequence, although with a greater risk of grade 3-4 AEs: https://t.co/9jC2oMI4Az

— NatureRevClinOncol (@NatRevClinOncol) September 7, 2022

Phase 2 single-arm study | Neoadjuvant Cemiplimab for stage II to IV cutaneous squamous-cell carcinoma.

13 Sep, 2022 | 13:11h | UTC

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Neoadjuvant Cemiplimab Induces Promising Pathologic Complete Response in CSCC – Cancer Network

Commentary on Twitter

A phase 2, multicenter study showed that four doses of neoadjuvant cemiplimab (anti–PD-1 antibody) led to a pathological complete response in 51% of patients with locally advanced cutaneous squamous-cell carcinoma. #ESMO22 https://t.co/NbICkb5kLM pic.twitter.com/a67fgxKBLy

— NEJM (@NEJM) September 12, 2022

RCT | Five-year analysis of adjuvant Pembrolizumab or placebo in stage III melanoma.

13 Sep, 2022 | 13:03h | UTC

Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma – NEJM Evidence

Phase 2 RCT | Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease.

11 Sep, 2022 | 22:25h | UTC

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial – The Lancet

3-year outcomes of a RCT | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma.

2 Sep, 2022 | 13:04h | UTC

First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743 – Annals of Oncology

Original Study: Randomized trial: First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma

Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management.

2 Sep, 2022 | 13:02h | UTC

Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management – International Journal of Dermatology

RCT | Optical coherence tomography vs. punch biopsy for diagnosis of basal cell carcinoma.

31 Aug, 2022 | 11:31h | UTC

Optical coherence tomography versus punch biopsy for diagnosis of basal cell carcinoma: a multicentre, randomised, non-inferiority trial – The Lancet Oncology (link to abstract – $ for full-text)

News Release: 66% of diagnostic biopsies for common skin cancer can be avoided using Michelson Diagnostics’ VivoSight OCT laser scanner – PR Newswire

RCT | Talimogene Laherparepvec plus Pembrolizumab not better than placebo-Pembrolizumab in patients with advanced melanoma.

26 Aug, 2022 | 13:09h | UTC

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma – Journal of Clinical Oncology

RCT | Therapeutic value of sentinel lymph node biopsy in patients with melanoma.

4 Aug, 2022 | 14:05h | UTC

Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial – JAMA Surgery (free for a limited period)

Invited Commentary: Prognostic or Therapeutic—The Role of Sentinel Lymph Node Biopsy in Contemporary Practice – JAMA Surgery (free for a limited period)

Cohort Study | Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas.

1 Aug, 2022 | 12:03h | UTC

Association between excision margins and local recurrence in 1407 patients with primary in situ melanomas – Journal of the American Academy of Dermatology International

Commentary: Margin Size Associated With Risk of Local Recurrence From Melanoma In Situ – AJMC

Cohort Study | Clinical outcomes and risk stratification of early-stage melanoma micrometastases.

1 Aug, 2022 | 12:04h | UTC

Clinical Outcomes and Risk Stratification of Early-Stage Melanoma Micrometastases From an International Multicenter Study: Implications for the Management of American Joint Committee on Cancer IIIA Disease – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary on Twitter

‼️ Patients with low-risk (pT1b-pT2a) #melanoma may still develop high-risk sentinel node metastases ➡️ https://t.co/cBVdpR6xrG #JCO #melsm @marc_moncrieff pic.twitter.com/TW0WHp5brA

— Journal of Clinical Oncology (@JCO_ASCO) July 27, 2022

Single-arm phase 2 study | Lenvatinib plus Pembrolizumab for melanoma with confirmed progression on a PD-1 or PD-L1 inhibitor given as monotherapy or in combination.

1 Aug, 2022 | 11:48h | UTC

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression — More than a fifth of patients responded to lenvatinib-pembrolizumab combination – MedPage Today (free registration required)

NICE Guideline Update | Melanoma: assessment and management.

28 Jul, 2022 | 13:21h | UTC

Melanoma: assessment and management – National Institute for Health and Care Excellence

RCT | Efficacy and safety of topical hypericin photodynamic therapy for early-stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides).

28 Jul, 2022 | 13:09h | UTC

Efficacy and Safety of Topical Hypericin Photodynamic Therapy for Early-Stage Cutaneous T-Cell Lymphoma (Mycosis Fungoides): The FLASH Phase 3 Randomized Clinical Trial – JAMA Dermatology (free for a limited period)

Commentary on Twitter

The findings of this randomized clinical trial indicate that synthetic hypericin photodynamic therapy is effective in early-stage patch and plaque mycosis fungoides−cutaneous T-cell lymphoma and has a favorable safety profile. https://t.co/hHfDESptQF

— JAMA Dermatology (@JAMADerm) July 21, 2022